MENU
Showcases Stock ranks Forex

Allogene Therapeutics Inc (ALLO)
15.96  0.5 (3.23%) 08-08 16:00
Open: 15.37 Pre. Close: 15.46
High: 16.075 Low: 15.5
Volume: 2,060,452 Market Cap: 2,292M
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 16.09 - 16.137 16.137 - 16.19
Low: 15.357 - 15.414 15.414 - 15.479
Close: 15.857 - 15.945 15.945 - 16.044
Stock Technical Analysis
Overall:     
Target: Six months: 18.78
One year: 21.93
Support: Support1: 12.60
Support2: 10.46
Resistance: Resistance1: 16.08
Resistance2: 18.78
Pivot: 13.79
Moving Averages: MA(5): 14.45
MA(20): 13.40
MA(100): 10.06
MA(250): 14.01
MACD: MACD(12,26): 0.88
Signal(12,26,9): 0.72
%K %D: %K(14,3): 96.22
%D(3): 83.81
RSI: RSI(14): 69.53
52-Week: High: 27.86
Low: 6.43
Change(%): -24.5
Average Vol(K): 3-Month: 2094
10-Days: 1444
Price, MAs and Bollinger Bands
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.

[ ALLO ] has closed above the upper band by 4.7%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 39.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
Stock chart
Stock News
Sun, 07 Aug 2022
Allogene Therapeutics (ALLO) Set to Announce Quarterly Earnings on Tuesday - Defense World

Wed, 03 Aug 2022
Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences - Investor Relations | Allogene Therapeutics

Wed, 27 Jul 2022
Allogene Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022 - Investor Relations | Allogene Therapeutics

Sun, 17 Jul 2022
Allogene Therapeutics (NASDAQ:ALLO) Shares Gap Up to $11.86 - Defense World

Tue, 12 Jul 2022
Allogene Therapeutics Appoints Scientific Pioneer Stephen Mayo to its Board of Directors - Investor Relations | Allogene Therapeutics

Wed, 08 Jun 2022
Allogene Therapeutics Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to ALLO-501A for Large B Cell Lymphoma - Investor Relations | Allogene Therapeutics

Financial Analysis
Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  NASDAQ Global Select
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M)
Shares Float (M) 143.60
% Held by Insiders 81780000.00
% Held by Institutions 29.93
Shares Short (K) 22060
Shares Short Prior Month (K)
Stock Financials
EPS -290360000.000
Book Value (p.s.)
Profit Margin
Operating Margin -147.00
Return on Assets (ttm) 601.5
Return on Equity (ttm) -17.6
Qtrly Rev. Growth 205000.0
Gross Profit (p.s.) -181.455
Sales Per Share -57.400
EBITDA (p.s.) -330345440.000
Qtrly Earnings Growth -2.20
Operating Cash Flow (M)
Levered Free Cash Flow (M) -203.72
Stock Valuation
PE Ratio
PEG Ratio -5.28
Price to Book value
Price to Sales -0.28
Price to Cash Flow 1.47
Stock Dividends
Dividend
Dividend Yield
Dividend Growth 22430000.000

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android